

Study Protocol:
Development and internal validation of a NYHA
functional class prediction algorithm for patients
with (severe to moderate) heart failure

Jonathan-F. Baril

November 10, 2017

Abstract

BACKGROUND: [NEED TO UPDATE]

OBJECTIVE: To develop and validate an NYHA functional class prediction algorithm for patients with (severe to moderate) heart failure

STUDY QUESTIONS: [NEED TO UPDATE]

HYPOTHESIS: [NEED TO UPDATE]

DESIGN METHODOLOGY: Sets, composed of one model for each target NYHA class (II & II), of multivariate hidden (pure- or semi-) Markov models.

SETTING: Tertiary care clinic specializing in the management of heart failure (The Heart Function Clinic at Toronto General Hospital, a part of the University Health Network (UHN) in Toronto, Canada) from November 2017 to April 2017.

PARTICIPANTS: consecutive sample of n consenting heart failures patients participating in program evaluation and quality improvement efforts for Medly, a telemonitoring platform used and developed for the test site. [Development; Internal Validation]

PRIMARY OUTCOME: NYHA functional classification as assessed by patient's attending cardiologist at clinic visits during study period.

RESULTS: TBD

CONCLUSIONS: TBD

[Classification; Development; Internal Validation]

1 Introduction

1.1 Background & Objectives

Heart failure, the complex chronic terminal phase of all cardiovascular disease, is slowly becoming a worldwide silent pandemic [1]. The symptoms of heart failure are complex and difficult to manage for both patients and their physicians [2–4]. Care is made even more difficult because there is no reliable objective method for assessing the moment-to-moment state of given patients HF, never mind determining if it is likely to worsen [5–7]. The current clinical gold standard for communicating a patient's state of Heart Failure is the New York Heart Association (NYHA) functional classification [8, 9]. This system grades a patient's degree of heart failure based on the physician's interpretation of patient reported symptoms (mainly with respect to their degree of exercise/activity intolerance). Despite these limitations clinical evidence and medical research have established many important relationships between a patient's NYHA class and their prognostic outcomes [7, 10].

Finding an objective means of determining a patient's NYHA class would provide a great boon to both heart failure care and research as it would cause intra- and inter-physician and patient assessments of heart failure class to more consistent [7, 11, 12]. Doing so would make communication of patient heart failure states in research, clinic notes, or other medical documentation more transparent and reliable.

Subjectivity in the current NYHA classification is introduced through two primary sources: patients and clinicians. Clinician, who readily identify these as issues, have already made steps to try and determine ways to eliminate this subjectivity [7]. One of the common clinical tests used is the 6 minute walk test (6MWT), where a patient is asked to walk as far as they can (being permitted to rest as needed) over a hard flat surface over the period of 6 minutes; the total distance walked is then used as an indicator of the aerobic capacity of the individual and by inference their degree of heart failure [13]. The development of the 6MWT typifies the general approach being taken to improve this particular area of clinical practice. Much research revolves around trying to identify or create tests that measure physical fitness, maximum exercise capacity or some proxy thereof [14–21]. These tests are then used to infer a patient's symptom response to exercise in their everyday life in order to compare it to the NYHA classification of that same patient. Typically a high level of physical fitness is assumed to imply less exercise intolerance in everyday life, which then implies a lower NYHA classification [14, 18, 21]. These tests are, almost without exception, run in a controlled clinical environment and are supervised by trained staff. As a result they generally do not measure the patient's real world response to physical exertion, in contrast to the aim of the NYHA functional classification.

In general these tests revolve around measuring a patient's exertion over a period of time [13, 14, 16–18, 20, 21]. Exertion is usually calculated by raw distance traveled (being generally more convenient to measure) [13, 14, 16, 18], patient step count (which can be linked to distance if the patient's stride length

is known) [20,22–28], movement recorded by raw accelerometer data [21,29–31], or even difficulty (e.g. surface incline, resistance band strength) [22,27] or energy consumption (e.g. Metabolic Equivalents: METS) [8,14,19] of exercise being attempted.

While these tests have shown that measures of exertion over time (whether distance, step count or otherwise) are correlated to the NYHA functional classification of patients there often remains a notable gap in the explanatory power of these measures. For example Demers et al. found that for the 768 patients in their multi-centre study the “baseline 6MWT distance was ... moderately inversely correlated to the New York Heart Association functional classification (NYHA-FC) ($r = -0.43$, $P = .001$)” [32]. In other words, distance travelled seemed to only explain approximately 18.5% of the variance in the data ($r^2 = 0.1849$). This is probably unsurprising since NYHA functional class is not predominantly attempting to ascertain maximal exercise capacity but rather the degree of abnormally symptomatic response to exercise. Therefore tests, measures, or metrics which can reliably mirror NYHA functional class will likely need to measure not just exertion but patient response to that exertion - beyond the simply binary response of ‘not being able to continue the exertion demanded’ (the case for all the previously mentioned tests). In fact, it is our hypothesis that when attempting to relate the results of a test back to NYHA functional classification, tests that account for patient response to exertion will have superior predictive capacity (whether measured by correlation, classification accuracy, or other metric as appropriate for comparing the tests in question) compared to those tests that simply measure patient exertion.

Heart rate, which has prognostic value by itself, is an obvious and simple metric that can be used to assess patient/cardiac response to exercise [15,33–36]. As an example then, a test that simultaneously measures heart rate along with an exertion measure such as distance traveled or step count would be much better positioned to provide an assessment of a patient’s specific response to exertion.

It turns out that modern commercially available activity/fitness trackers can fairly reliably track both minute-by-minute step count (the exertion measure) as well as heart rate (the exertion response). These devices are a promising means of providing a human memory-independent and precise (even if not a 100% accurate) picture of a patient’s response to activity [19,24–26,37–41]. “Replacing” patient memory with activity trackers would eliminate a significant source of subjectivity and potential error in trying to determine a patient’s level of activity intolerance.

An intelligent classification algorithm could then be trained to mimic expert grading by an experienced “model” physician (and to compensate for inherent biases and inaccuracies in the recording sensors). By imbuing artificial intelligence into such an algorithm so that it could translate relevant data into the desired clinical outcome (NYHA classification) or a sufficiently equivalent outcome (an ‘NYH-AI’ or ‘NYHAI’ classification if you will) we could provide a way for to assess a patient’s functional classification in an objective, universally-consistent manner that still leverages the advantages and benefits of the existing

'traditional' NYHA classification method. In other words a continuously worn activity tracker combined with an intelligent classification algorithm executed by a computer could remove the subjectivity introduced by both clinical and patients providing a more consistent and purely objective means of measuring patient response to exertion and assessing NYHA class.

The general the objectives of this study are as follows:

1. The primary goal is to establish a robust and general foundational framework for use by researchers, data scientists and engineers to develop and assess intelligent NYHA machine classification algorithms that can be trained to mirror grading by experienced physicians with the goal of making NYHA classification more consistent and reliable for the medical research and clinical community.
2. A secondary goal is to initiate the start the collection of continuously monitored activity and heart data from heart failure patient at the test site for use in this and future studies and algorithm development.
3. The tertiary aim is to perform an pilot study using data collected during an initial brief data collection period as well as the foundational framework developed, to explore if Hidden Markov Models show promise for classifying NYHA classification algorithm.

2 Methods

2.1 Source of Data/Study Design

The pilot study data to be used for development of the Hidden Markov Model based classifier will be sourced between December 2017 and April 2017 from an open (prospective) cohort of adult outpatients at a tertiary care clinic specializing in the management of advanced heart failure (The Heart Function Clinic at Toronto General Hospital, a part of the University Health Network (UHN), in Toronto, Canada). Since patients will be enrolled on a rolling basis throughout this period, patients who have been monitored for less than 1 month at the end of the study period will be excluded from this initial pilot development data set.

The same dataset used for algorithm development will be used for internal validation of the algorithm since a suitable external validation dataset is not currently available.

2.2 Participants

The cohort will consist of all consecutive patients prescribed, enrolled and using (i.e. being monitored by) the Medly telemonitoring program (Medly) consenting to be included in program evaluation and quality improvement efforts for Medly.

A patient will be considered for inclusion into Medly only if they are:

1. a consenting adult (18+ years of age),
2. diagnosed with heart failure,
3. followed by a licensed cardiologist at the UHN Heart Function Clinic who in turn bears the primary responsibility for the management and care of that patients heart failure diagnosis (the responsible or attending cardiologist),
4. sufficiently capable of speaking and reading English, or having an informal caregiver (spouse, parent, etc.) capable of the same so as to both:
 - (a) undergo the process of and provision of informed consent for participation in the Medly program
 - (b) understand and follow the text prompts provided by the Medly patient-side application
5. capable of complying with the use of Medly (e.g. capable of truthfully answering symptom questions, capable of safely and correctly using the peripherals such as the weight scale, activity tracker and blood pressure cuff)

While there are no explicit exclusion criteria for the study, we note that the decision to prescribe or exclude a patient from the Medly program is ultimately up to the professional judgement of the attending cardiologist. As of the time of writing a total of 6 attending cardiologists use Medly as part of patient care although one of the cardiologists (the medical director of the clinic) is disproportionately responsible for a majority of the patients monitored.

During the study period patients will receive no special treatment with regards to the medical interventions used and prescribed to them. Their cardiologist are expected to continue treat patients according to the established standard-of-care at the Heart Function Clinic. It should be noted that the standard-of-care is expected to continue to evolve during the study period to reflect current clinical best practice. It is expected that the Medly platform will continue to be updated to reflect this evolving standard-of-care and will receive regular features updates, upgrades and bug-fixes as released by the Medly development team from time to time.

It is also worth noting that as part of regular heart failure care patients may receive medications (such as beta-blockers) which are known to affect heart rate. However, since this data is not available in a conveniently and easily accessible format it will not be included in the dataset at the present time due to time constraints although we do discuss how it might be included for the sake of completeness.

2.3 Outcome

The outcomes of interest are the New York Heart Association (NYHA) functional class for each patient. While competing methods of reporting the severity

of heart failure experienced by a patient exist, the NYHA classification is arguably the most commonly used system for functional classification of heart failure and many well established relationships have been identified between a patient's NYHA class and prognostic outcomes for the condition.

2.3.1 Risk Groups

Patients in the study are classified into one of four risk groups. NYHA class I, II, III & IV. As a specialized tertiary care centre the Heart Function Clinic rarely sees NYHA class I patients as they are often asymptomatic with regards to their heart failure, or at least rarely require the specialized level of care offered by the clinic. NYHA class IV patients, while seen at the clinic, often derive little benefit with regards to physical activity monitoring since these patients are known to be often bedridden or severely activity intolerant. Classes II and III however represent a classification challenge since the dividing line between mild and marked activity intolerance can sometimes be unclear especially given the inherent subjective nature of the NYHA classification; training a machine to classify between class II & II patients is therefore likely to produce the greatest benefit to clinical and medical research so we focus on these two risk groups in this study.

NYHA class is typically assessed for every patient with known cardiac disease (usually first objectively verified through the use of some sort of medical imaging modality). It is then reassessed at every clinic visit by the physician responsible for patient's care. At minimum, the physician will pose questions to attempt to elucidate the patients' degree of exercise intolerance, for example: "How far can you walk before becoming short of breath?", or "How many flights of stairs can you climb before needing to stop?". The physician will then select an NYHA class based on their clinical experience, professional judgement according to the NYHA class definitions. These definitions are copied below for the reader's convenience [42]:

- I: "Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain."
- II: "... slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain."
- III: "... marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain."
- IV: "Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased."

2.3.2 Label Assignment

At the study site (the Heart Function Clinic) NYHA class is assessed for each patient as part of each visit at the Heart Function Clinic. The assessment is performed by the physician seeing the patient (resident, fellow or otherwise) and verified by the attending physician. Within the context of this study it means that outcome measures are recorded at the date of on-boarding and then only recorded sporadically during the study period as patients return for clinic visits. The interval between regularly scheduled clinic visits varies between 1-2 weeks to 3-6 months. Patients with more severe or less stable conditions will visit more frequently. As well, patient's who are undergoing a change in their heart failure medication (e.g. up- or down- titrating) will also visit more frequency, usually a few times within a period of a few weeks as the medication is adjusted. Since patients were on-boarded on a rolling basis over a period of 5 months there is no guarantee that a given patient (especially the more stable patients) will return to physically visit the clinic within the study period and be reassessed for any potential change in their NYHA class.

The sporadicity and instability of the outcome measure presents a significant challenge to this study for several reasons. There is however a further challenge with regards to NYHA label assignment: physicians are notoriously unreliable and inconsistent at assessing NYHA class in the first place [43–47]. Carroll et al. report: (bibliographic reference numbers updated to reflect ours)

[One study] used two physicians to estimate NYHA functional class in 75 patients on the same day without chronic heart failure, reporting an interrater reliability of 56% (weighted kappa = 0.41) [44]. In a second study, two cardiologists assessed the same 50 chronic heart failure patients on the same day in random order, observing 54% agreement in NYHA classes [46]. In a third study, two physicians assigned NYHA class to 56 patients with stable angina within the same hour, resulting in the highest reported agreement of 75% [45]. Among these studies, disagreement by more than one functional class was low and, for the most part, was concentrated on determining the discrete differences between Classes II and III. Taken together, the reliability of the NYHA system is limited in the few trials that have measured it directly. [43]

Kubo et al. came up with a standardized NYHA questionnaire for use at multi-centre studies based on the published definitions by the American Heart Association to try and improve intra-rater agreement and reliability [47]. Even using this questionnaire they reported a concordance of only about 60% between the 3 independent physician graders and a concordance of about 75% for the (independent) reviewers [47]. Concordance for “repeat grading of 30 randomly selected questionnaires” was admittedly much higher at 90% but we doubt this last result is highly extensible to typical clinical practice [47].

In other words, in half of the studies outlined above inter-physician agreement on NYHA class fared only marginally better than random and even in

those studies where physician agreement was much better than random there was still often disagreement in essentially 1/4 of the cases. Training an algorithm on data that is suspect to this degree is essentially already doomed to fail if the objective is to be able to unequivocally determine the true underlying NYHA class of a patient - the fact that patient class can change between clinic visits without being perceived or detected by the rating physician (and therefore updated for our training set) only serves to doom such a goal even more.

So why bother? Well it is an unwritten truth in engineering practice that while bad standards are bad, they are at least consistently so which does make them much easier to fix. Everyone can agree that a bad standard is bad, but it's universal use and acceptance does at least provide some value. So, the initial value an automated NYHA classification algorithm will not necessarily be in it's ability to unequivocally determine the true underlying NYHA class of a patient but rather that it rates patients in a universally consistent manner. For example consider the Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE), both screening tests used for detection of mild cognitive impairment (a suspected precursor to Alzheimer's disease) [48]. Both MoCA and MMSE test results have their limitations with regards to detection of degrees of cognitive impairment with varying sensitivity between the tests leading some researchers to try and develop alternative but both the MoCA and MMSE test are still often used to by researchers and clinicians to communicate the degree of a patient's impairment because, importantly, they provide a consistent and reliable even if sometime imprecise way of assessing patient state [48–50].

Along this vein, by creating a system that adequately mimics the classification decisions of an accepted authoritative source (i.e our expert clinician) we can essentially create such a consistent test for heart failure classification while maintaining the existing utility of NYHA class. Disclosing this algorithm would make it possible for clinicians and researchers to use the algorithm as a 'virtual' independent rater to generate a common and completely consistent way of communicating heart failure state regardless of major differences in clinician training, experience, patient context, etc. It is also for this reason that the data collected from patients for use in this study is limited to computer harvested data (such as that from activity trackers) or to independently verifiable data that is measured according to a universally (or near-universal) accepted standard (such as patient age, or prescribed beta-blocker dosage) - to ensure the algorithm results are as universally applicable as possible.

In this way, the fact that patient class may change between clinic visits is of secondary concern since it can be rectified later as it speaks more to the ability of the algorithm to predict the underlying NYHA class rather than mimic the rating source. However, in the interest of not having completely unreliable source data, since we cannot guarantee NYHA functional class stability between patient visits for a given patient, we propose using the Medly symptoms questionnaire as a proxy outcome and as a means of detecting suspected drops/aggravations in NYHA class. As part of Medly, patients are prompted every morning by the telemonitoring system to answer the following series of questions to ascertain their current condition. All of these questions have a

clinical relevance to a patients current heart failure condition and so have the potential to alert us of a potential change (i.e. drop) in a patient's class. Note that questions 7-11 only appear if a patient has answered yes to any of question previous questions (1-6).

1. Have you fainted?
2. Has your ICD (Implantable Cardiverter Defibrillator) gone off?
3. Has your breathing as night worsened?
4. Do you have more chest pain than usual?
5. Are you more tired than usual?
6. Are you more short of breath than usual?
7. Are your ankles swollen?
8. Do you feel that your heart is beating unusually?
9. Do you feel lightheaded?
10. Did you have to stop any of your usual daily activities because of your health?
11. Enter the number of pillows you used to sleep.

While all of the questions target some specific symptom or set of symptoms experienced by heart failure patients, questions 1, 2, 4-6, & 8-10 specifically try to determine whether there have been an increase in a patients exercise/activity intolerance. Since a patient's level of activity intolerance is the primary determinant of their NYHA classification, an increase in the frequency of affirmative responses to these questions over a sustained period, say 2 weeks, would be a strong indicator that a patient's NYHA class may have changed. Baseline response frequency can be determined from the 2 week period immediately following the first clinic visit moving to the 2 week period immediately preceding the last clinic visit for all following visits. Absent of a confirmation of NYHA class change at the next clinic visit a statistically significant change, at the $p = 0.1$ level of significance, from the baseline frequency of response would be a reasonable indicator that a patient's NYHA class may have experienced a level of instability of the 2 week period worth following up on. To follow-up and verify a possible NYHA class change patients would be requested to complete the standardized questionnaire developed by Kubo et al. [47]. The completed questionnaire would then be provided to the clinician responsible for that patient so they can perform a reassessment of the patients NYHA class.

The patient data streams will be segmented into two-week chunks with each chunk representing one time-unit of analysis so that the algorithm will be made to attempt to independently classify (and trained on) each of these two-week chunks of data.

2.4 Predictors

The predictors used to generate the prediction outcome are as follows:

1. Heart Rate [beats per minute] - recorded using commercially available activity-tracker (Fitbit Charge HR, Charge 2 or Alta HR) continuously throughout the day.

Fitbit activity-trackers measure heart rate using a technique known as photoplethysmograph (PPG) [22,51]. The devices are equipped with signal emitter(s) - light emitting diodes (LEDs), generally of different frequencies - and matched signal detector(s) - light detecting optical sensors matched to the frequency of the LEDs. The signal emitter and detectors are placed in close proximity to a patient's skin so that the light can be directed to shine on their skin. In this way the light emitted by the diodes can be reflected back off of the skin to detected and quantified by the signal detector. The degree of light reflected by the skin depends on many various factors, but importantly it depends on the volume and oxygenation of the blood in underlying blood vessels and capillaries of the skin. The greater the volume of blood the more the signal is attenuated and therefore the lower the signal measured at the detector. Since the volume of blood in the vessel varies with the state of the cardiovascular cycle it is possible to infer the patient's pulse rate from the detected waveform. While the signal waveform is less reliable and information-laden than an electrocardiograph waveform it does have the advantage of being non-invasive, inexpensive, highly portable and easy to measure, not requiring the use of unruly wired electrodes. We recommend the following comprehensive review by J. Allen of the technical details and intricacies of photoplethysmography technology for the interested reader [52].

The Fitbit wearable collects this raw PPG data and using Fitbit's proprietary PurePulse algorithm to infer the heart rate from the waveform data [51]. The exact details and functioning of this algorithm is not disclosed to the general public and subject to change (and be upgraded) at any time. Although the algorithm is not infallible and not endorsed by Fitbit for clinical use, Fitbit devices which are regularly independently reviewed by researchers usually score as one of the most accurate commercial activity trackers (generally with about at least 80-90%+ accuracy on heart rate) [22,24,25,38,39,53]. Heart rate data is available for every 1 second interval if the device is set in workout mode (for compatible devices like the Fitbit Charge HR), and every 5 seconds otherwise [22].

Once the raw waveform is processed the heart rate data is uploaded using the Bluetooth wireless communication standard to a paired device (typically a smartphone). The smartphone then relays this information to Fitbit servers where it is stored for use by the user, by Fitbit and by authorized applications. This is done automatically and seamlessly without user intervention so long as the devices (Fitbit, Phone and Fitbit servers) are able to maintain communication with each other. The Fitbit is able

to store data for a week without uploading it before it begins to aggregate and overwrite old data.

Fitbit exposes an applications programming interface (API) which can be used by authorized parties to access user data (with the requisite user permission) on Fitbit servers. Using this API the back-end servers that power part of the Medly telemonitoring platform are able to retrieve study participant data from the Fitbit servers. Study participant activity data uploaded to Fitbit servers was automatically requested by the Medly servers on a daily basis. Heart rate data was requested only for every 60 second interval during the study period due to storage constraints.

2. Step Count [steps per minute] - recorded using commercially available activity-tracker (Fitbit Charge HR, Charge 2 or Alta HR) continuously throughout the day.

Fitbit activity-trackers measure step count using an integrated 3-axis accelerometer [54]. Accelerometers convert the acceleration they experience into useful electrical signals. 3-axis accelerometers in particular measure accelerations in all 3 orthogonal cartesian axes and so can record movements in any direction. The algorithms that interpret the various acceleration signals into specific human motions are complicated and far beyond the scope of this work. As with PurePulse algorithm, the exact algorithm used by Fitbit to convert raw accelerometer data into step count is proprietary and not released to the general public [54]. The step count algorithm is also known not to be 100% reliable, although it continuously gets tuned, upgrade and improved by Fitbit [55]. As with the heart rate data independently reviews by researchers usually score Fitbit devices as being generally high accurate in their daily measurement of step counts (again usually with at least 80-90%+ accuracy on step count measurements) [24–26, 29, 38, 39, 56]

As with the heart rate data, once the Step Count is inferred from the raw accelerometer data the Step Counts are uploaded using the Bluetooth wireless communication standard to a paired device (typically a smartphone). The smartphone again relays this information to Fitbit servers where it is stored for use by the user, by Fitbit and by authorized applications. This is done automatically and seamlessly without user intervention so long as the devices (Fitbit, Phone and Fitbit servers) are able to maintain communication with each other. The Fitbit is also able to store this data for a week without uploading it before it begins to aggregate and overwrite old data.

Fitbit also exposes the applications programming interface (API) for step count data which the Medly servers use to request the data on a daily basis. Step count data will also only be requested for every 60 second interval (matching the heart rate data resolution) during the study period due to storage constraints.

3. Patient Demographic/Meta Data - recorded when prescribed Medly (carried over from onboarding process before this study), namely:
 - (a) Sex [Male or Female]
 - (b) Age [years]
 - (c) Handedness [left or right]
4. Prescribed Medications - recorded at on-boarding and updated as required at every clinic visit, sourced from clinic notes:
 - (a) Beta Blockers [mean daily dose in mg]

All of the aforementioned predictors are stored on the Medly telemonitoring platform servers. The individual data elements are linked to a unique Medly user account for each study participant. Data stored on Medly servers in this format is then easily exportable and convertible from it's native format to a format more suitable for further processing using an analytic software of choice (e.g. R).

2.5 Sample Size

As a general heuristic (or even simply a frame of reference) machine learning practitioners generally consider data sets on the order of hundreds of samples to be relatively small [57–59]. The exact size of a data set required to properly train a typical Hidden Markov Model (or any machine learning algorithm in general) depends on a number of different factors including the, method of classification, complexity of the classifier, separation between classes, variance and presence of noise in the data, amongst many other factors. The noisier, the more complex and the greater the variance in the data, typically the larger the dataset required to achieve good performance. There is no upper limit for how much data should be used for training but there point at which increasing input data begins to yield diminishing returns in improving predictive performance [59]. The exact relationship between training set size and predictive performance for an algorithm and problem in question is often shown as a 'learning curve' graph (which plots training set size versus prediction error(s)). To the best of the author's knowledge the learning curve for this particular application (or a sufficiently analogous application) has not yet been determined. However, given that we expect that the data collected in this study will be relatively noisy and complex we expect that the model may lean towards requiring more data rather than less data. Therefore, we collect as much data as was available in order to not prematurely limit the power nor the generalizability of the algorithm developed.

All this being said, given a present recruitment rate of approximately 1 patient per week at the Heart Function Clinic we expect to be able to accumulate a dataset of approximately 30 patients over the 30 week period from the beginning of December 2017 to the end of April 2018. Based on a previous study

performed at the Heart Function Clinic several years ago we expect a distribution of approximately 40/15/40/5 for patients in classes II, undetermined II/III, III and IV respectively - so approximately 12, 4 to 5, 12 and 1 to 2 patients in each corresponding class [60].

2.6 Missing Data

Due to the nature of the data collection methods used we don't expect to have a lot of missing data. However, despite initial expectations missing data is still often an inevitable reality for scientific studies. We handle missing data in the following manner:

Missing Heart Rate and Step Count data is not explicitly reported by the activity tracker. If the device is not being worn it will report both step count and heart rate values as 0 from which we can infer that the data is missing. If step count is zero while heart rate is non-zero we can infer that the patient is simply at rest. We suspect that use of the Fitbit will be more of an all-or-nothing affair where patients put on the device at the beginning of the day and keep it on all day as opposed to constantly using and removing the device. As a result, patients with less than 30 minutes of average daily 'wear time' during each analysis period will be flagged since they will likely have insufficient data for each day for the system to perform a reliable classification.

Blood pressure data which always comes as a set of systolic/diastolic readings are imputed using non-parametric multiple imputation using the 'missForest' R package (which uses a random forest algorithm to predict missing values and makes no assumption about the underlying distribution of the data and supports both missing categorical and continuous variables) [61,62]. Weight, symptom questionnaire responses, heart failure treatments to date and prescribed medications are dealt with using the same approach.

Patients without any specified NYHA class (i.e. missing outcome data) are ignored completely, however gaps in NYHA class outcomes are imputed using the same approach as missing predictors (namely blood pressure, weight, etc.).

2.7 Statistical Analysis Methods

2.7.1 Normalization

Before using the data to train the classification algorithm the predictors will be normalized to values between 0 and 1 (after imputation of missing data as required). The normalization procedure for each of the predictors is as follows:

1. Heart Rate [beats per minute] - linear scaling using: $min = 0$, $max = 208 - 0.7 * age$ (where patient's age is measured in years) [63]
2. Step Count [steps per minute] - linear scaling using: $min = 0$, $max = 300$
 - (a) Sex [Male or Female]: $Male = 0$, $Female = 1$
 - (b) Age [years]- linear scaling: $min = 18$, $max = 150$

- (c) Handedness [left or right]: $Left = 0$, $Right = 1$
- 3. Prescribed Medications [mean daily dose in mg] -
 - (a) Beta Blockers - linear scaling: Acebutolol $min = 0$, $max = 1200$ [64] & Atenolol $min = 0$, $max = 300$ & Bisprolol $min = 0$, $max = 20$ & Carvedilol $min = 0$, $max = 80$ & Labetalol $min = 0$, $max = 2400$ & Metaprolol $min = 0$, $max = 450$ & Nadolol $min = 0$, $max = 320$ & Pindolol $min = 0$, $max = 60$ & Propranolol $min = 0$, $max = 640$ & Timolol $min = 0$, $max = 60$ [65,66]

2.7.2 Model Development

The algorithm we develop to classify patients into their corresponding NYHA class will be designed to perform binary classification of class II and III patients, or multi-class classification of class II, III and IV dependant on our ability to capture class IV patients for analysis. The following section outlines the details of the development in both cases (which are very similar except for the addition of a third class).

To perform the classification we create and train multivariate hidden Markov models for each of the target risk groups (NYHA class II, III, IV).

[[ELABORATION ON MARKOV MODELS: STILL IN PROGRESS]]

Diagrams, explanations etc. are still in progress. I need to organize the following into something more coherent but the basic substance is included for completeness.

What they are: Markov Models - probabilistic state machine where transitions between states are performed randomly according to pre-specified transition probabilities. These probabilities along with the number of states form the model parameters

Hidden Markov Models - where the underlying states are hidden (i.e. not observable). We only know the number of states, and don't know the specific state the system may be in

Markov chains/processes - are stochastic (random) processes that satisfy the Markovian property: the probability of the immediate next (and all next) future states is dependant only the present state (and therefore not on any other states the system may have existed in). Alternatively this is referred to as the memoryless property; essentially that the markov process has no memory of the past.

Hidden Markov Models generally operate under the Markovian assumption, so they assume that process/data they model adheres to the Markovian property. This is not always true, and in fact Hidden Markov Models in certain cases have been found to be able to fairly successfully model process that sometimes even grossly violate this Markovian assumption. Which brings us to:

Hidden Semi-Markov Models - are like hidden markov models but they officially relax the 'Markovian' assumption of the model by permitting the model

to retain memory of how long it has been in a certain state (usually to force it to not exist in a state for too long).

Part of contributions of this study will be to determine if Hidden Markov Models are suitable for modelling patient activity and heart rate data which violates the Markovian assumption 'demanded' of Hidden Markov Models.

The complete set of parameters that must be determined for a Hidden Markov Model are as follows: the emission probabilities the state probabilities the starting probabilities For a Hidden semi-Markov Model there is an additional set of probabilities the transition probabilities

Determining the best Hidden Markov Model parametrization for given data stream is an intractable problem. That being said there is a known algorithm for efficiently computing locally optimal parameterizations for a steam. Generally speaking these class of algorithms are known as expectation-maximization (EM) algorithm but the specific algorithm used for Hidden Markov Model training is the Baum-Welch algorithm which is able to run more efficiently due to some simplifying assumptions that can be made due to the nature of Hidden Markov Models.

This being said, the Baum-Welch algorithm is unable to determine all of the parameters by itself. Some of the parameters must be provided as 'initial conditions' for the algorithm to execute. Typically these are the emission probabilities, the starting probabilities (and the transition probabilities). Although it is possible (and encouraged) to try various combinations of parameters to determine the most effective set - in fact more fully featured software libraries will sometimes offer to do this automatically, it is up to the researcher to determine appropriate 'initial conditions.'

In our case we use the 'mhsmm' package for the R software platform [67, 68] which requires the user to provide the number of desired states, the fixed emission probabilities as well as a starting point for the state probabilities and starting probabilities (which the algorithm adjusts as it searches for a local optimum).

===== **So far:** I've used this as starting points -

States: 3 (plan to sweep them from 3 to 6-8 depending on computational power available. Computation complexity increases to the square of number of states (i.e. 3 states = 9 possible transitions, 6 states = 36 possible transitions, 8 states = 64 possible) which makes high state HMM's unwieldy to train.

Starting Probabilities: 1 for one of the states, 0 for all others since based on Simon's data patients spend most of the time in the non-active state.

Starting Transition Probabilities: Uniform = $\frac{1}{\text{number of possible transitions}}$ Emission Probabilities: based on the Simon's data, emission probabilities look to be gamma distributed. The distribution parameters are set such that the distribution centers around a peak identified in the data (20 steps/min, 80 steps/min, 100 steps/min for 3 state HMM) In the case where a gamma distribution doesn't work out the package implements normal distributions which we can try instead.

The transition probabilities: For exploration of Hidden semi-Markov Models the plan is to use a gamma distribution and to try it with the distribution

centered around a certain period of time, sweeping that period of time in 1hr intervals from 1 to 12 hrs (or possibly the maximum human bladder retention period).




Figure 1: P0: Preprocessing Data

Since it is probably unreasonable to assume that there is no time-dependence in state changes due to the dynamic nature of human exercise and activity (e.g. people who are performing high-intensity activity are less likely to continue as time goes by since they get tired) we also train equivalent multivariate hidden semi-Markov models for each of the target risk groups to explore the effect of relaxing the Markovian assumption (or time-independence) of pure Markov models.

We identified five candidate sets of variables for inclusion into the predictive models:

1. heart rate + step count
2. the above + weight
3. the above + blood pressure
4. the above + Symptom Questionnaire Responses specifically targeting activity intolerance
5. the above + Prescribed Medications

We opted not to use the 'Heart Failure Treatments to Date' data since we suspected that it would render the model far too complex rendering it even more prone to over fitting and preferred to focus our efforts on the five models already identified.

To further trim the set of variables we propose running a Pearson cross-correlation analysis on the collected data to identify the sets of highly correlated variables. These sets can be trimmed down to the single most useful predictor (whether clinically relevant, easiest to collect, or otherwise). Eliminating needlessly redundant information should help reign in the model complexity.

To verify the classification algorithm we can an internal validation, recognizing that such a validation is likely to produce optimistic results. To verify the algorithm and models we select sets of hidden (semi-)Markov models - one for each risk group - and ask each model in the set to calculate the likelihood that a two-week window of data from a test patient was generated using that model. The model with the highest associated probability predicts the outcome (NYHA class) for that window of test data. By performing this test on each two-week window (incremented by day) for each patient and comparing the predicted value with the most recent physician reported value we can determine the sensitivity and specificity of each classification model set and thereby identify the best model.

2.7.3 Model Performance Assessment

After development of an classification algorithm it will be important to assess how well the classifier is able to correctly assess patient NYHA class. Since performance evaluation measures differ for binary and multi-class classifiers this

section discuss both. Measures of classification accuracy for a classification test or algorithm (regardless of the number of supported classes) can be reported in a confusion matrix, an example of which is shown below [69–72].

Clinical Classification							
Algorithm Classification		II	III	IV	Predictive Value:		
		II	a	b		c	$\frac{a}{a+b+c}$
		III	d	e		f	$\frac{e}{d+e+f}$
		IV	g	h		i	$\frac{i}{g+h+i}$
Sensitivity:		$\frac{a}{a+d+g}$	$\frac{e}{b+e+h}$	$\frac{i}{c+f+i}$	Accuracy:		
Specificity:		$\frac{e+f+h+i}{b+c+e+f+h+i}$	$\frac{d+f+g+i}{a+c+d+f+g+i}$	$\frac{d+e+g+h}{a+b+d+e+g+h}$	$N = \frac{a+e+i}{\sum_{all\ cells}}$		

From the cells of a confusion matrix we can, amongst other measures, determine the:

- a) *sensitivity, recall, or true positive rate* of a test: the proportion of patients correctly identified as belonging to the particular test class e.g. class II [70, 72–76]. Phrased mathematically, letting x_c represent those patients belonging to a particular class c (e.g. class II) from the set of all classes C and \hat{x}_c represent those patients predicted by the test as belonging to this particular class then the sensitivity is $P(\hat{x}_c|x_c)$. In other words sensitivity measures how reliably the test identifies patients belonging to a particular class by labelling them with that class.
- b) *specificity, or true negative rate* of a test: the proportion of patients correctly identified as not belonging to the particular test class e.g. not class II [70, 72–76]. Phrased mathematically, letting $!x_c$ represent those patients not belonging to a particular class c (e.g. not class II) and $!\hat{x}_c$ represent those patients predicted by the test as not belonging to class c then the sensitivity is $P(!\hat{x}_c|!x_c)$. In other words, specificity measures how reliably the test identifies patients not belonging to a given class by labelling with a class other than that given class.
- c) *fall-out, or false positive rate* of a test: the proportion of patients positively identified by the test as belonging to a particular class but actually belonging to a different test class e.g. identified as class II but actually class I [70, 72, 74–76]. Phrased mathematically using the same definitions as for the previous measures then the false positive rate is $P(\hat{x}_c|!x_c) = 1 - specificity$. In other words, the false positive rate identifies how over-eager the test is at labelling patients as belonging to a particular class in an effort to not miss patients that actually belong to that class - it is the 'fall-out' or 'collateral damage' in the 'affirmative' labelling.

- d) *precision* or *positive predictive value* of a test: the proportion of patients correctly classified as belonging to a particular test class amongst all those identified by the test as belonging to that class [72–76]. Phrased mathematically using the same definitions as for the previous measures then the positive predictive value is $P(x_c|\hat{x}_c)$. In other words, the positive predictive value measures how likely a patient is, for each given class, to actually belong the class it has been labelled as.
- e) *accuracy* of a test: the proportion of patients correctly classified by the test into their true class [70, 72, 74–76]. Phrased mathematically using the same definitions as for the previous measures the accuracy of the test is $\bigcup P(\hat{x}_c = x_c)$ for all $c \in C$ which in the case of mutually exclusive classes simplifies to $\sum_{c \in C} P(\hat{x}_c = x_c)$. In other words, the accuracy measures how well a test correctly classifies patients into their respective classes. Unfortunately, the way accuracy is calculated makes it highly sensitive to the underlying base rate of occurrence of each of the classes, namely it preferentially weighs classes that occur more frequently in the underlying population often limiting it’s usefulness as a summary metric.
- f) *F score*, *F₁ score*, or *F-measure* of a test: an alternative to accuracy that is less sensitive to the underlying base rate of occurrence for each of the classes. It is the harmonic mean of *precision* and *recall* for that class [70, 72, 74–76]. Phrased mathematically using the same definitions as for the previous measures the F score of the test is:
- $$F_1 = 2 * (\frac{1}{recall} + \frac{1}{precision})^{-1}$$

To aid in comparing performance, many of the above test measures can be visualized in various ways. One of the most useful is the Receiver Operating Characteristic (ROC) curve which shows the trade off between the *sensitivity* and *fall-out* of a test [69–73, 77]. We can generate the ROC curve for each risk group by plotting the corresponding risk group *false positive rate* vs *true positive rate*. Alternatively, we can also generate a precision-recall (PR) plot to better understand the trade-off relationship between the precision vs recall for each group [70–73]. While both of these plots are very useful for visual comparison of the performance trade-offs between different algorithms (or even different formulations or parametrizations of the same algorithm) it is often very useful to be able to distil these visual plots into a single performance metric to make a final determination on algorithm performance. This is especially true in the case where an algorithm designer would like to automate the search for the optimal algorithm (parametrization or formulation).

Both the ROC and precision-recall plots are easily interpretable and can be summarized by measuring the areas under each of the ROC and precision-recall curves (ROC AUC and precision-recall AUC respectively) [69–72]. Plots with an AUC value closer to 1 represent better overall classifiers (AUC values lower than 0.5 indicate performance that is worse than random classification). AUC values are convenient for comparing multiple ROC or precision-recall plots but

are generally not recommended as the sole decision criteria [69–72]. This is simply because a unidimensional metric inevitably obfuscates the underlying curve (recall the moral of Anscombe’s quartet) [78].

In the case of a binary (mutually exclusive two-class) classifier (e.g. where the decision must be made to classify a patient into NYHA class II or III only), which can be summarized using a single ROC or precision-recall (PR) curve (since, by symmetry, improving the classification of one class reduces the misclassification of the second and vice versa), selecting either the ROC AUC or precision-recall AUC is natural, expedient and generally very effective [69–72]. However the selection of ROC AUC over precision-recall (PR) AUC depends on the underlying class balance of the dataset. David et al. proved a ‘surprising theorem that a curve dominates in ROC space if and only if it dominates in PR space’ but ‘that an algorithm that optimizes the area under the ROC curve is not guaranteed to optimize the area under the PR curve’ [71]. Precision-recall curves, and by extension the PR AUC, are more appropriate for use in datasets with highly skewed class distributions (e.g. a prevalent negative class with few positive class - very common in the field of information retrieval) [71, 72, 74]. Precision-recall curves however are more computationally complicated to solve although several packages exist for the R programming language (amongst others) to calculate PR AUC, ROC AUC and all the various metrics discussed thus far [79, 80].

In the case of multi-class classifiers (e.g. where the decision presented is to classify a patient into any of the four classes, or even just three of the four classes: e.g. II-IV) the situation is more complicated. Multi-class classifiers cannot be summarized using a single ROC or precision-recall curve in the same way as binary classifiers [72, 74, 77, 81–83]. There have been attempts by researchers to develop an equivalent AUC metric by expressing it in an ‘equivalent probabilistic form’ [81], or by plotting multi-dimensional ROC or precision-recall surfaces - although this metric is more accurately termed the volume-under-the-curve (VUC) for the 3 class case, hyper-volume-under-the-curve (hVUC) for the 4 class case, and so on [77]. None of these metrics however has gained widespread acceptance. The most accepted approach however appears to be to completely forgo calculation of the AUC in the first place and instead perform a micro- or macro-average of an underlying performance measure (such as specificity) [72, 74, 82].

The macro-average of a measure, is calculated in the same way as one might compute the ‘classical’ mean of a the measure by simply taking the mean of the measure output values. The micro-average however involves instead first taking the mean of the inputs to the measure computation function and using those input mean values to calculate a single measure output value [76]. The difference is sometimes clearer and more obvious when expressed mathematically.

Given a set of k classes $C = c_1, c_2, \dots, c_k$ and a binary performance measure $B(m_{1,c}, m_{2,c}, \dots, m_{n,c})$ that can be calculated for a given class c (and for each class c) based on a values in the confusion matrix $m_{1,c}$ to $m_{1,n}$ for that class (which in our case would be the main confusion metric measures: true positives & negatives and false positives & negatives) then the macro-average is for

performance measure B is calculated as [75, 76, 84]:

$$B_{macro} = \frac{1}{k} \sum_{j=1}^k B(m_{1,j}, m_{2,j}, \dots, m_{n,j}) \quad (1)$$

In comparison the micro-average is calculated as [75, 76, 84]:

$$B_{micro} = B(\sum_{j=1}^k m_{1,j}, \sum_{j=1}^k m_{2,j}, \dots, \sum_{j=1}^k m_{n,j}) \quad (2)$$

Unfortunately, it is still an open question as to whether micro-averaging or macro-averaging produces more reliable results. Van Asch quoting a paper by Sebastiani outlines the state of the debate in the early 2000's [76]:

There is no complete agreement among authors on which is better. Some believe that micro-averaged performance is somewhat misleading (...) because more frequent topics are weighted heavier in the average [Wiener et al. 1995, page 327] and thus favour macro-averaging. Others (actually, the majority of researchers) believe that topics should indeed count proportionally to their frequency, and thus lean towards micro-averaging. [85]

The choice is sometimes performance measure dependent; Forman et al., based on series of simulations they performed, advanced the majority position that micro-averaging should be the preferred method for calculating the F score (a common alternative to accuracy in the information retrieval domain) since it is more unbiased in the common case where class imbalance exist in those datasets, especially where that class imbalance is large or the classifier is inaccurate in the first place [75]. A decade and a half later, the issue, at least in practice, appears to still not be settled. A quick review of recent literature shows that researchers appear to prefer to simply use and report both the micro- and macro-averaged results for their metrics (usually precision, recall, accuracy and F score) [86–89]. Some have even eschewed micro- and macro-averaging in favor of developing new metrics, such as the Multiclass Performance Score (MPS), designed specifically for use with multi class classifiers [83]. In keeping with common practice we plan to report on the micro- and macro-averaged precision, recall, accuracy and F score of our algorithm. But, in our case, given our intent to integrate our classification algorithm into a larger clinical decision support application at the Heart Failure Clinic we do not have the freedom of waffling between all of these measures but rather must make a determination of which single measure is most appropriate for the evaluation of our candidate algorithms for optimization. To do this we return to the basics.

The fundamental difference between macro- and micro-averaging is how the weighting is distributed. In macro-averaging equal weight is given to each class. In micro-averaging equal weight is given to each individual patient classification decision. To Forman et al.'s point, it's not that micro-averaging is more

unbiased so much as it's particular bias was more suitable given the field of application considered by Forman et al. (namely document retrieval where giving adequate weighting to less frequently occurring individual results - typically the documents to be retrieved - is more preferable). In a sense, every measure is biased - the question is simply which bias is more helpful for the application in question.

In our case we also expect to have an imbalance of persons in each class for various reasons:

- a) sicker patients (closer to class IV) are more likely to die and therefore those classes are likely to be more under represented,
- b) the UHN Heart Failure clinic typically sees more advanced cases of Heart Failure and is less likely to see patients in the lowest class (class I) making this class more likely to be under represented¹,
- c) based on our previous experience with the Medly tele-monitoring platform, class IV patients are less likely to be prescribed the platform as a clinical intervention (and thus be eligible for the study) since physicians perceive them to be less likely to benefit from the intervention. As a result, this class is again more likely to be under represented.

Of course we will need to examine the final recruitment cohort to confirm that our expectations do indeed turn out. Have established that “microaveraged results are ... really a measure of effectiveness on large classes in a test collection. To get a sense of effectiveness on small classes, [one] should compute macroaveraged results” [90]. This would indicate that the use of macro-averaging will provide the most suitable bias for our particular situation since, as discussed, NYHA class IV is likely to be under represented in our population. Since macro-averaging will treat every class considered with equal weighting optimizing our algorithm using a macro-averaged metric is more likely to ensure that classification performance of a smaller NYHA class IV will be treated with the same priority as any other class. Optimizing using micro-averaging would instead preferentially weigh improvements (or decreases) in algorithm performance that largely affect those classes whose patients are more represented in the dataset (NYHA class II or III) which we suggest is undesirable.

Of course we do note that the use of microsimulation (detailed later) will allow us to compensate for any significant imbalances in our development dataset should we so choose. The issue of micro- vs macro-simulation therefore is perhaps less critical for this particular study as it may be for future (external) validation studies.

So putting aside the issue of micro- and macro-averaging for a moment. Thus far we have entirely avoided the issue of misclassification cost. For binary classification problems misclassification cost is generally glossed over since there

¹which again, is also why although the general approach proposed is easily extensible to this class, NYHA class I patients are generally disregarded in our study

is only a single cost for incorrect classification. This cost can be taken into account after computation of performance measures. However, in certain multi class classification problems (such as this one) certain types of misclassification can be deemed to be more costly than others and so there is not necessarily a single cost for misclassification. In our case: misclassification of a class II patient into class IV is a more severe error, and thereby most costly error, than misclassification of a class II patient into class III. It is a relatively easy task to design an algorithm to account for this and so the difficulty here mostly revolves around how to quantify the exact costs of different degrees of misclassification (costs which also could very well change over time) [83]. This challenge is rendered even more difficult since classification of patients into NYHA class, as already mentioned, is already an unreliable art [43, 44, 46, 47]. And where there is already a relative paucity of published research regarding the reliability of NYHA classification by physicians there is complete drought when it comes to attempts to quantify the real costs of misclassification. Fortunately selecting an incorrect misclassification cost in this context will not actually reduce the accuracy of a selected output algorithm. Instead it would direct the optimization algorithm to search for a suboptimal algorithm, not that any optimization algorithm even guarantees that it has found the single most (i.e. globally) optimal algorithm in the first place [91]. Given the aforementioned consideration and the lack of readily available data documenting concrete misclassification costs we propose the following as a reasonable selection of costs to use as a starting point in this study. Of course, we invite the interested reader to improve on our approach.

Recall that *true positive rate* (*sensitivity/recall*) measures the proportion of patients correctly identified as belonging to a particular test class. Given a confusion matrix of n_c classes which can be encoded as a $n_c \times n_c$ mathematical matrix M_c as follows, demonstrated, without loss of generality, using a $n_c = 3$ class confusion matrix:

$$\begin{array}{c} \text{Algorithm} \\ \text{Classification} \end{array} \begin{array}{c} \text{Clinical Classification} \\ \begin{array}{|c|c|c|} \hline & \text{II} & \text{III} & \text{IV} \\ \hline \text{II} & a & b & c \\ \hline \text{III} & d & e & f \\ \hline \text{IV} & g & h & i \\ \hline \end{array} \end{array} \Rightarrow M_c = \begin{bmatrix} a & b & c \\ d & e & f \\ g & h & i \end{bmatrix}$$

Let the grand sum of the elements of M_c be equal to k , and the sum of the elements in each column j of M_c be equal to k_j . For our example:

$$k_1 = a + b + c$$

$$k_2 = d + e + f$$

$$k_3 = g + h + i$$

The rectangular $n_c \times n_c$ averaging matrix K for M_c must be defined either as :

$$K = K_{micro} = \frac{1}{k} J_{n_c} = \frac{1}{k} \begin{bmatrix} 1 & 1 & \dots & 1 \\ 1 & 1 & \dots & 1 \\ \vdots & \vdots & \ddots & \vdots \\ 1 & 1 & \dots & 1 \end{bmatrix}_{n_c \times n_c}, \text{ for micro-averaging}$$

or

$$K = K_{macro} = \frac{1}{n_c} J_{n_c} = \begin{bmatrix} \frac{1}{k_1} & 0 & \dots & 0 \\ 0 & \frac{1}{k_2} & \dots & 0 \\ \vdots & \vdots & \ddots & \vdots \\ 0 & 0 & \dots & \frac{1}{k_{n_c}} \end{bmatrix}_{n_c \times n_c}, \text{ for macro-averaging}$$

We can therefore represent the calculation of the *true positive rate* or *recall* of M_c as Frobenius inner product ($\langle \cdot, \cdot \rangle_F$; which returns the sum of the component-wise inner product of two matrices) of a weighting matrix W_r , and the Hadamard product (i.e. element-wise product: \odot) of the desired micro- or macro-averaging matrix K and the confusion matrix M_c :

$$recall = \langle W_r, K \odot M_c \rangle_F \quad (3)$$

The weight matrix for the (classic definition of the) *true positive rate* would be as follows:

$$W_r = \begin{bmatrix} 1 & 0 & \dots & 0 \\ 0 & 1 & \dots & 0 \\ \vdots & \vdots & \ddots & \vdots \\ 0 & 0 & \dots & 1 \end{bmatrix}_{n_c \times n_c}$$

It may be clearer to see why this is the case given an example. The above implies the following weighting for our 3 class example (displayed in a confusion matrix grid). Moving forward we will use this confusion matrix inspired grid format to display the weights since it makes explicit the corresponding classes and classification source for each weight value.

Weights		Clinical Classification		
Algorithm Classification		II	III	IV
	II	1	0	0
	III	0	1	0
	IV	0	0	1

Each true positive (along the diagonal of the table) for the class are each counted as 1 correct classification and each false negatives is counted as contributing 0 correct classifications to the overall *true positive rate* 'score'. So for our example 3 class M_c matrix the recall is calculated as follow. We use micro-averaging for the sake of clarity, the technique is equivalent for macro-averaging but more clumsy as a result of the different weightings for each column. Recall the formula for recall is:

$$recall = \langle W_r, K \odot M_c \rangle_F$$

and so for micro-averaging becomes:

$$recall = \langle W_r, K_{micro} \odot M_c \rangle_F$$

substituting in for K_{macro} ,

$$recall = \langle W_r, \frac{1}{k} M_c \rangle_F$$

substituting in both W_r and M_c ,

$$recall = \frac{1}{k} \left\langle \begin{bmatrix} w_{a,1} & w_{b,2} & w_{c,3} \\ w_{d,1} & w_{e,2} & w_{f,3} \\ w_{g,1} & w_{h,2} & w_{i,3} \end{bmatrix}, \begin{bmatrix} a & b & c \\ d & e & f \\ g & h & i \end{bmatrix} \right\rangle_F$$

then the Frobenius inner product of the matrices evaluates to:

$$recall = \frac{1}{k} (aw_{a,1} + bw_{b,2} + cw_{c,3} + dw_{d,1} + ew_{e,2} + fw_{f,3} + gw_{g,1} + hw_{h,2} + iw_{i,3})$$

or equivalently:

$$recall = \frac{1}{k} (aw_{a,1} + ew_{e,2} + iw_{i,3}) + \frac{1}{k} ((dw_{d,1} + gw_{g,1}) + (bw_{b,2} + hw_{h,2}) + (cw_{c,3} + fw_{f,3})) \quad (4)$$

We pause to take note that if we let:

$$w_{tp} = w_{a,1} = w_{e,2} = w_{i,3}$$

and:

$$w_{fn} = w_{d,1} = w_{g,1} = w_{b,2} = w_{h,2} = w_{c,3} = w_{f,3}$$

and recalling that k is simply the sum of all the cells:

$$k = a + b + c + d + e + f + g + h + i$$

then equation 4 becomes:

$$recall = \frac{w_{tp}(a + e + i) + w_{fn}((d + g) + (b + h) + (c + f))}{a + b + c + d + e + f + g + h + i} \quad (5)$$

i.e.:

$$recall = \frac{w_{tp}(a + e + i) + w_{fn}((d + g) + (b + h) + (c + f))}{(a + e + i) + ((d + g) + (b + h) + (c + f))} \quad (6)$$

Here we have essentially grouped the true positive counts:

$$True\ Positives = TP = a + e + i$$

and false negative counts (sub-grouped for each class):

$$False\ Negatives = FN = FN_{class1} + FN_{class2} + FN_{class3} = (d + g) + (b + h) + (c + f)$$

i.e.

$$recall = \frac{w_{tp}TP + w_{fn}FN}{TP + FN} \quad (7)$$

and for $w_{tp} = 1$ and $w_{fn} = 0$ we can clearly see here that we have simply replicated the classic *True Positive Rate*, *recall* formula:

$$recall|_{classic} = P(\hat{x}_c | x_c) = \frac{TP}{TP + FN} \quad (8)$$

But, we have gained added flexibility because we now have weight parameters ($w_{a,1}$, $w_{b,2}$, $w_{c,3}$ and so on) that we can now manipulate to alter how the recall function scores each individual type of classification or misclassification instead of a blanket $w_{tp} = 1$ for each correct classification (which is not inherently problematic in our situation) and $w_{fn} = 0$ for each incorrect classification (which is the problem we are attempting to resolve).

In order to penalize more egregious misclassifications we propose the use of the following adjusted weight matrix (for a 3 class classifier. A 4 class classifier would require a different weight matrix):

Weights		Clinical Classification		
Algorithm Classification		II	III	IV
	II	+1	0	-1
	III	0	+1	0
	IV	-1	0	+1

The above weight matrix is derived from the following rules, which we simultaneously demonstrate using an example sub-set of the a confusion matrix sub-set (shown immediately below) and it's corresponding *True Positive Rate* score - we let the default score equal x :

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	a	$+1 * a$
	III	d	$+0 * d$
	IV	g	$\underline{-1 * g}$

\Rightarrow

score: $1a - 1g = x$

1. In keeping with the classic *True Positive Rate* formula an increase in the number of misclassifications, *ceteris paribus*, should not cause an increase in the *True Positive Rate* score.

increase in the number of class II patient's misclassified as class III:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	a	$+1 * a$
	III	$d + n$	$\Rightarrow +0 * (d + n)$
	IV	g	$\underline{-1 * g}$

score: $x + 0$

increase in the number of class II patient's misclassified as class IV:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	a	$+1 * a$
	III	d	$\Rightarrow +0 * d$
	IV	$g + n$	$\underline{-1 * (g + n)}$

score: $x - n$

2. A decrease in misclassification severity for a given patient, *ceteris paribus*, should cause an increase in the *True Positive Rate*.

class II patient misclassification improvement to III from IV:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	a	$+1 * a$
	III	$d + 1$	$\Rightarrow +0 * (d + 1)$
	IV	$g - 1$	$\underline{-1 * (g - 1)}$
					score: $x + 1$

class II patient misclassification improvement to II from III:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	$a + 1$	$+1 * (a + 1)$
	III	$d - 1$	$\Rightarrow +0 * (d - 1)$
	IV	g	$\underline{-1 * g}$
					score: $x + 1$

3. An increase in misclassification severity for a given patient, *ceteris paribus*, should cause a decrease in the *True Positive Rate*.

class II patient misclassification deterioration to III from II:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	$a - 1$	$+1 * (a - 1)$
	III	$d + 1$	$\Rightarrow +0 * (d + 1)$
	IV	g	$\underline{-1 * g}$
					score: $x - 1$

class II patient misclassification deterioration to IV from III:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	a	$+1 * a$
	III	$d - 1$	$\Rightarrow +0 * (d - 1)$
	IV	$g + 1$	$\underline{-1 * (g + 1)}$
					score: $x - 1$

4. The health of any arbitrary patient should be considered as having at least the same value as the health of any arbitrary other patient². In other words, *Ceteris paribus*, an algorithm that is able to decrease the misclassification severity from baseline for a number of patients, at the cost of increasing the misclassification severity from baseline for an equivalent number of other patients should be considered strictly as not performing any better than an equivalent algorithm that simply classifies patients at those baselines.

class II patient misclassification improvement to III from IV and
class II patient misclassification deterioration to IV from III:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	a	$+1 * a$
	III	$d + 1 - 1$	$+0 * (d + 1 - 1)$
	IV	$g - 1 + 1$	$-1 * (g - 1 + 1)$

\Rightarrow

$-1 * (g - 1 + 1)$

score: $x + 0$

class II patient misclassification improvement to II from III and
class II patient misclassification deterioration to III from II:

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	$a + 1 - 1$	$+1 * (a + 1 - 1)$
	III	$d - 1 + 1$	$+0 * (d - 1 + 1)$
	IV	g	$-1 * g$

\Rightarrow

$-1 * g$

score: $x + 0$

class II patient misclassification improvement to II from III and
class II patient misclassification deterioration to IV from III:

²This sort of accounting of human life is admittedly rather crude, having a tendency to lead to a, probably, over simplistic and myopic utilitarian view of justice, equality and fairness [92]. It is the author's admission that this is not necessarily an ideal and perhaps a future reader from a more enlightened time will be able to improve on this crude assumption if ever society is able to solve the complex calculus of human life valuation. However this assumption does at least reflect a not uncommonly accepted viewpoint, or at least an ideal, of present (western) cultural and societal thought and so is at least, in the author's humble opinion, is a not unreasonable starting point.

		Clinical Classification			
		II	III	IV	
Algorithm Classification	II	$a + 1$	$+1 * (a + 1)$
	III	$d - 2$	$+0 * (d - 2)$
	IV	$g + 1$	<u>$-1 * (g + 1)$</u>
					score: $x + 0$

And so using the adjusted weight matrix instead of an identify matrix (i.e. the weight matrix for the classic definition of *recall*) we can instead guide to optimization algorithm to not only to prefer algorithms that are strictly better at classifying patients into their corresponding class but when patients are misclassified to prefer algorithms that misclassify them less incorrectly.

To summarize: how specifically we report and assess the performance of our classifier will depend primarily on how many classes it supports. Either way though the selection a final candidate algorithm we will use machine optimization (although the exact method is not yet determined ³) to iterate though various parametrizations of the classification algorithm to identify more performant versions. For the purpose of optimization the performance of the algorithm will be evaluated based on a relevant performance metric depending on how many classes it supports. For a binary classifier we will use the area under the receiver operating characteristic curve (AUC ROC). For a multi-class classifier we will use a modification to the *recall* performance metric where more extreme misclassification of patients will be more heavily penalized instead of penalized identically to less extreme misclassifications (correct classifications will be treated identically to the classical interpretation of the performance measure). This modification will allow us to select for algorithms that are not just more correct, but also 'less wrong'. We will report standard measures of predictive accuracy for the final classification algorithm developed whether binary (class II or III), or multi-class (II, III and IV) - dependant on our ability to capture class IV patients for analysis. These measures will include the (classically defined) *sensitivity/recall*, *specificity*, *fall-out*, *precision* and *F-score*. These standard measures will be reported as raw measures for a binary classifier and as macro- and micro-averaged measures for a multi-class classifier. We note that the assessment of the final classification algorithm will be performed by running the classifier against the (internal) validation dataset (which is the same as the development dataset) and as a result we expect that evaluation of algorithm performance to be optimistic.

2.8 Development vs. Validation

Since we reuse a single dataset the setting, eligibility criteria, outcome, and predictors remain unchanged for both datasets. Since model development and

³Possible candidates include: simulated annealing, genetic algorithms, amongst others [91]

performance assessment is also performed using the same dataset we expect the reported performance to be optimistic.

3 Results

3.1 Participants

3.2 Model Development

3.3 Model Specification

3.4 Model Performance

3.5 Model-updating

4 Discussion

4.1 Limitations

4.2 Interpretation

4.3 Implications

5 Other Information

5.1 Supplementary Information

5.2 Funding

Funding for this project was provided by the:

Centre for Global eHealth Innovation (Heart Function Clinic?)
Canadian Institutes of Health Research (Government of Canada)
Government of Ontario
University of Toronto

References

- [1] M. R. Mehra and J. Butler, “Heart Failure: A Global Pandemic and Not Just a Disease of the West,” *Heart Failure Clinics*, vol. 11, no. 4, pp. xiii–xiv, oct 2015. [Online]. Available: <http://www.ncbi.nlm.nih.gov/pubmed/26462110><http://linkinghub.elsevier.com/retrieve/pii/S1551713615000690>
- [2] Heart and Stroke Foundation, “2016 Report on the Health of Canadians: The Burden of Heart Failure,” 2016. [Online]. Available: <http://www.heartandstroke.com/atf/cf/%7B99452d8b-e7f1-4bd6-a57d-b136ce6c95bf%7D/2016-HEART-REPORT.PDF>

- [3] E. Seto, K. J. Leonard, J. a. Cafazzo, C. Masino, J. Barnsley, and H. J. Ross, "Self-care and quality of life of heart failure patients at a multidisciplinary heart function clinic." *The Journal of cardiovascular nursing*, vol. 26, no. 5, pp. 377–85, 2011. [Online]. Available: <http://www.ncbi.nlm.nih.gov/pubmed/21263339>
- [4] S. Lawrence, "Canada is failing our heart failure patients - Heart and Stroke Foundation of Canada," 2016. [Online]. Available: <http://www.heartandstroke.com/site/apps/nlnet/content2.aspx?c=ikIQLcMWJtE&b=3485819&ct=14816887>
- [5] J. Cox and C. D. Naylor, "The Canadian Cardiovascular Society Grading Scale for Angina Pectoris: Is It Time for Refinements?" *Annals of Internal Medicine*, vol. 117, no. 8, p. 677, oct 1992. [Online]. Available: <http://annals.org/article.aspx?doi=10.7326/0003-4819-117-8-677>
- [6] C. Raphael, C. Briscoe, J. Davies, Z. Ian Whinnett, C. Manisty, R. Sutton, J. Mayet, and D. P. Francis, "Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure," *Heart*, vol. 93, no. 4, pp. 476–482, apr 2007. [Online]. Available: <http://heart.bmj.com/cgi/doi/10.1136/hrt.2006.089656>
- [7] J. A. Bennett, B. Riegel, V. Bittner, and J. Nichols, "Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease," *Heart and Lung: Journal of Acute and Critical Care*, vol. 31, no. 4, pp. 262–270, 2002.
- [8] Heart Foundation, "New York Heart Association (NYHA) Classification," p. 1, 2014. [Online]. Available: [http://www.heartonline.org.au/media/DRL/New_York_Heart_Association_\(NYHA\)_classification.pdf](http://www.heartonline.org.au/media/DRL/New_York_Heart_Association_(NYHA)_classification.pdf)
- [9] American Heart Association, "Classes of Heart Failure," 2015. [Online]. Available: http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.WBY_myTla2s
- [10] A. Ahmed, W. S. Aronow, and J. L. Fleg, "Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function." *American heart journal*, vol. 151, no. 2, pp. 444–50, feb 2006. [Online]. Available: <http://www.ncbi.nlm.nih.gov/pubmed/16442912>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC2771182>
- [11] L. Goldman, B. Hashimoto, E. F. Cook, and A. Loscalzo, "Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale," *Circulation*, vol. 64, no. 6, pp. 1227–1234, 1981. [Online]. Available: <http://circ.ahajournals.org/cgi/doi/10.1161/01.CTR.64.6.1227>

- [12] B. A. Williams, S. Doddamani, M. A. Troup, A. L. Mowery, C. M. Kline, J. A. Gerringer, and R. T. Faillace, "Agreement between heart failure patients and providers in assessing New York Heart Association functional class," *Heart and Lung The Journal of Acute and Critical Care*, vol. 46, no. 4, pp. 293–299, jul 2017. [Online]. Available: <http://dx.doi.org/10.1016/j.hrtlng.2017.05.001>http://www.sciencedirect.com/science/article/pii/S0147956317300031?_rdoc=1&_fmt=high&_origin=gateway&_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb&dgcid=raven_sd_recommender_email&ccp=y
- [13] G. Roul, P. Germain, and P. Bareiss, "Does the 6-minute walk test predict the prognosis in patients with NYHA class II or III chronic heart failure?" *American Heart Journal*, vol. 136, no. 3, pp. 449–457, sep 1998. [Online]. Available: <http://linkinghub.elsevier.com/retrieve/pii/S0002870398702194>
- [14] G. J. Balady, R. Arena, K. Sietsema, J. Myers, L. Coke, G. F. Fletcher, D. Forman, B. Franklin, M. Guazzi, M. Gulati, S. J. Keteyian, C. J. Lavie, R. Macko, D. Mancini, and R. V. Milani, "AHA Scientific Statement Clinician's Guide to Cardiopulmonary Exercise Testing in Adults A Scientific Statement From the American Heart Association," *American Heart Association Exercise Clinical Cardiology; Council on Epidemiology and Prevention*. [Online]. Available: <http://circ.ahajournals.org/content/circulationaha/122/2/191.full.pdf>
- [15] N. Uth, H. Sørensen, K. Overgaard, and P. K. Pedersen, "Estimation of VO₂max from the Ratio between HR_{max} and HR_{rest} - the Heart Rate Ratio Method," *European Journal of Applied Physiology*, vol. 91, no. 1, pp. 111–115, 2004. [Online]. Available: <http://pure.au.dk/portal/files/14557663/UTH2004.pdf>
- [16] G. M. Kline, J. P. Porcari, R. Hintermeister, P. S. Freedson, A. Ward, R. F. McCarron, J. Ross, and J. M. Rippe, "Estimation of VO₂max from a one-mile track walk, gender, age, and body weight." *Medicine and science in sports and exercise*, vol. 19, no. 3, pp. 253–9, jun 1987. [Online]. Available: <http://www.ncbi.nlm.nih.gov/pubmed/3600239>
- [17] K. H. Cooper, *Aerobics*. Bantam Books, 1969.
- [18] S. Saalasti and A. Pulkkinen, "Method and system for determining the fitness index of a person," 2012. [Online]. Available: <https://www.google.com/patents/US20140088444>
- [19] N. F. Butte, U. Ekelund, and K. R. Westerterp, "Assessing Physical Activity Using Wearable Monitors: Measures of Physical Activity," *Med. Sci. Sports Exerc*, vol. 44, no. 1S, pp. 5–12, 2012. [Online]. Available: <https://pdfs.semanticscholar.org/9fad/9108623002f685aecb7ecc98f77075057384.pdf>

- [20] Ap507, “Study shows slow walking pace is good predictor of heart-related deaths University of Leicester,” 2017. [Online]. Available: <https://www2.le.ac.uk/news/blog/2017-archive/august/study-shows-slow-walking-pace-good-predictor-of-heart-related-deaths>
- [21] S. Zhao, K. Chen, Y. Su, W. Hua, S. Chen, Z. Liang, W. Xu, Y. Dai, Z. Liu, X. Fan, C. Hou, and S. Zhang, “Association between patient activity and long-term cardiac death in patients with implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators,” *European Journal of Preventive Cardiology*, vol. 24, no. 7, pp. 760–767, 2017. [Online]. Available: <http://journals.sagepub.com/doi/10.1177/2047487316688982>
- [22] R. Abdulmajeed, “The Use of Continuous Monitoring of Heart Rate as a Prognosticator of Readmission in Heart Failure Patients,” Ph.D. dissertation, University of Toronto, 2016.
- [23] Z. J. Eapen, M. P. Turakhia, M. V. McConnell, G. Graham, P. Dunn, C. Tiner, C. Rich, R. A. Harrington, E. D. Peterson, and P. Wayte, “Defining a Mobile Health Roadmap for Cardiovascular Health and Disease,” *Journal of the American Heart Association*, vol. 5, no. 7, p. e003119, jul 2016. [Online]. Available: <http://jaha.ahajournals.org/lookup/doi/10.1161/JAHA.115.003119>
- [24] D. Wen, X. Zhang, X. Liu, and J. Lei, “Evaluating the Consistency of Current Mainstream Wearable Devices in Health Monitoring: A Comparison Under Free-Living Conditions.” *Journal of medical Internet research*, vol. 19, no. 3, p. e68, mar 2017. [Online]. Available: <http://www.jmir.org/2017/3/e68/http://www.ncbi.nlm.nih.gov/pubmed/28270382>
- [25] F. El-Amrawy, M. I. Nounou, K. Volpp, M. Patel, N. Lin, and R. Lewis, “Are Currently Available Wearable Devices for Activity Tracking and Heart Rate Monitoring Accurate, Precise, and Medically Beneficial?” *Healthcare Informatics Research*, vol. 21, no. 4, p. 315, 2015. [Online]. Available: <https://synapse.koreamed.org/DOIX.php?id=10.4258/hir.2015.21.4.315>
- [26] H.-S. An, G. C. Jones, S.-K. Kang, G. J. Welk, and J.-M. Lee, “How valid are wearable physical activity trackers for measuring steps?” *European Journal of Sport Science*, vol. 17, no. 3, pp. 360–368, mar 2017. [Online]. Available: <https://www.tandfonline.com/doi/full/10.1080/17461391.2016.1255261>
- [27] S. E. Bromberg, “Consumer Wristband Activity Monitors as a Simple and Inexpensive Tool for Remote Heart Failure Monitoring,” 2015.
- [28] A. Abeles, R. M. Kwasnicki, C. Pettengell, J. Murphy, and A. Darzi, “The relationship between physical activity and post-operative length of hospital stay: A systematic review,” *International Journal of Surgery*,

- jul 2017. [Online]. Available: <http://linkinghub.elsevier.com/retrieve/pii/S1743919117305721>
- [29] D. B. Bornstein, M. W. Beets, W. Byun, G. Welk, M. Bottai, M. Dowda, and R. Pate, "Equating accelerometer estimates of moderate-to-vigorous physical activity: In search of the Rosetta Stone," *Journal of Science and Medicine in Sport*, vol. 14, no. 5, pp. 404–410, sep 2011. [Online]. Available: <http://linkinghub.elsevier.com/retrieve/pii/S1440244011000752>
 - [30] M. Awais, S. Mellone, and L. Chiari, "Physical activity classification meets daily life: Review on existing methodologies and open challenges," *Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, EMBS*, vol. 2015-Novem, pp. 5050–5053, 2015.
 - [31] M. Jehn, S. Prescher, K. Koehler, S. Von Haehling, S. Winkler, O. Deckwart, M. Honold, U. Sechtem, G. Baumann, M. Halle, S. D. Anker, and F. Koehler, "Tele-accelerometry as a novel technique for assessing functional status in patients with heart failure: Feasibility, reliability and patient safety," *International Journal of Cardiology*, vol. 168, pp. 4723–4728, 2013. [Online]. Available: http://ac.els-cdn.com/S016752731301396X/1-s2.0-S016752731301396X-main.pdf?_tid=6725a990-9263-11e7-a20a-00000aacb35f&acdnat=1504634309_515452e6ea9b9329b9241c3c24cf211e
 - [32] C. Demers, R. S. McKelvie, A. Negassa, and S. Yusuf, "Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure," *American Heart Journal*, vol. 142, no. 4, pp. 698–703, 2001.
 - [33] J. K. Moon and N. F. Butte, "Combined heart rate and activity improve estimates of oxygen consumption and carbon dioxide production rates." *Journal of applied physiology (Bethesda, Md. : 1985)*, vol. 81, no. 4, pp. 1754–61, oct 1996. [Online]. Available: <http://www.ncbi.nlm.nih.gov/pubmed/8904596http://jap.physiology.org/content/jap/81/4/1754.full.pdf>
 - [34] K. Imai, H. Sato, M. Hori, H. Kusuoka, H. Ozaki, H. Yokoyama, H. Takeda, M. Inoue, and T. Kamada, "Vagally mediated heart rate recovery after exercise is accelerated in athletes but blunted in patients with chronic heart failure," *Journal of the American College of Cardiology*, vol. 24, no. 6, pp. 1529–1535, nov 1994. [Online]. Available: http://ac.els-cdn.com/0735109794901503/1-s2.0-0735109794901503-main.pdf?_tid=ed8dfdfc-3c12-11e7-b77d-00000aabb0f6c&acdnat=1495143945_dcd737ecc3b5e6a44c2319032b42abbehttp://linkinghub.elsevier.com/retrieve/pii/0735109794901503
 - [35] J. S. Borer, M. Böhm, K. Swedberg, M. Komajda, J. Rey, S. Borer, I. Ford, A. Dubost-Brama, G. Lerebours, and L. Tavazzi, "Heart

- rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial,” *Articles 886 www.thelancet.com Lancet*, vol. 376, pp. 886–94, 2010. [Online]. Available: <http://repository.um.edu.my/10125/1/1-s2.0-S0140673610612597-main.pdf>
- [36] N. M. Arzeno, M. T. Kearney, D. L. Eckberg, J. Nolan, and C.-S. Poon, “Heart rate chaos as a mortality predictor in mild to moderate heart failure.” *Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference*, vol. 2007, pp. 5051–4, aug 2007. [Online]. Available: <http://ieeexplore.ieee.org/document/4353475/http://www.ncbi.nlm.nih.gov/pubmed/18003141>
- [37] R. Wang, G. Blackburn, M. Desai, D. Phelan, L. Gillinov, P. Houghtaling, M. Gillinov, C. MA, M. H, L. RMT, T. DJ, E.-A. F, and P. MS, “Accuracy of Wrist-Worn Heart Rate Monitors,” *JAMA Cardiology*, vol. 313, no. 6, pp. 625–626, oct 2016. [Online]. Available: <http://cardiology.jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2016.3340>
- [38] T. J. M. Kooiman, M. L. Dontje, S. R. Sprenger, W. P. Krijnen, C. P. van der Schans, and M. de Groot, “Reliability and validity of ten consumer activity trackers,” *BMC Sports Science, Medicine and Rehabilitation*, vol. 7, no. 1, p. 24, dec 2015. [Online]. Available: <http://bmcsportsscimedrehabil.biomedcentral.com/articles/10.1186/s13102-015-0018-5http://www.ncbi.nlm.nih.gov/pubmed/26464801http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4603296>
- [39] T. Ferguson, A. Rowlands, V. T. Olds, and C. Maher, “The validity of consumer-level, activity monitors in healthy adults worn in free-living conditions: a cross-sectional study,” *International Journal of Behavioral Nutrition and Physical Activity*, vol. 12, no. 1, p. 42, dec 2015. [Online]. Available: <http://www.ijbnpa.org/content/12/1/42>
- [40] F. Attal, S. Mohammed, M. Dedabrishvili, F. Chamroukhi, L. Oukhellou, and Y. Amirat, “Physical Human Activity Recognition Using Wearable Sensors.” *Sensors (Basel, Switzerland)*, vol. 15, no. 12, pp. 31314–38, 2015. [Online]. Available: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4721778&tool=pmcentrez&rendertype=abstract>
- [41] K. R. Evenson, M. M. Goto, and R. D. Furberg, “Systematic review of the validity and reliability of consumer-wearable activity trackers,” *International Journal of Behavioral Nutrition and Physical Activity*, vol. 12, no. 1, p. 159, dec 2015. [Online]. Available: <http://www.ncbi.nlm.nih.gov/pubmed/26684758http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4683756http://www.ijbnpa.org/content/12/1/159>

- [42] The Criteria Committee of the New York Heart Association, *Classification of Functional Capacity and Objective Assessment*, 9th ed. Boston, Mass.: Little, Brown and Co., 1994. [Online]. Available: http://professional.heart.org/professional/General/UCM_423811_Classification-of-Functional-Capacity-and-Objective-Assessment.jsp
- [43] S. L. Carroll, K. Harkness, and M. H. McGillion, "A Comparison of the NYHA Classification and the Duke Treadmill Score in Patients with Cardiovascular Disease," *Open Journal of Nursing*, vol. 4, pp. 774–783, 2014. [Online]. Available: <http://www.scirp.org/journal/ojnhttp://dx.doi.org/10.4236/ojn.2014.411083http://creativecommons.org/licenses/by/4.0/>
- [44] L. Goldman, B. Hashimoto, E. F. Cook, and a. Loscalzo, "Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale." *Circulation*, vol. 64, no. 6, pp. 1227–1234, 1981.
- [45] H. W. Christensen, T. Haghfelt, W. Vach, A. Johansen, and P. F. Hoiland-Carlsen, "Observer reproducibility and validity of systems for clinical classification of angina pectoris: comparison with radionuclide imaging and coronary angiography," *Clinical Physiology and Functional Imaging*, vol. 26, no. 1, pp. 26–31, jan 2006. [Online]. Available: <http://doi.wiley.com/10.1111/j.1475-097X.2005.00643.x>
- [46] C. Raphael, C. Briscoe, J. Davies, Z. Ian Whinnett, C. Manisty, R. Sutton, J. Mayet, D. P. Francis, and C. Raphael, "Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure," *Heart*, vol. 93, pp. 476–482, 2007. [Online]. Available: <http://heart.bmj.com/content/heartjnl/93/4/476.full.pdf>
- [47] S. H. Kubo, S. Schulman, R. C. Starling, M. Jessup, D. Wentworth, and D. Burkhoff, "Development and validation of a patient questionnaire to determine New York heart association classification," *Journal of Cardiac Failure*, vol. 10, no. 3, pp. 228–235, 2004. [Online]. Available: <http://www.sciencedirect.com/science/article/pii/S1071916403007450?via%3Dihub>
- [48] Z. S. Nasreddine, N. A. Phillips, V. Bedirian, S. Charbonneau, V. Whitehead, I. Collin, J. L. Cummings, and H. Chertkow, "The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment," *Journal of the American Geriatrics Society*, vol. 53, no. 4, pp. 695–699, apr 2005. [Online]. Available: <http://doi.wiley.com/10.1111/j.1532-5415.2005.53221.x>
- [49] P. White, "An immersive virtual reality navigational tool for diagnosing and treating neurodegeneration," 2016.
- [50] P. White, Z. Moussavi, and P. White, "Neurocognitive Treatment for a Patient with Alzheimer's Disease Using a Virtual Reality Navigational

- Environment,” *Journal of Experimental Neuroscience*, p. 129, nov 2016. [Online]. Available: <http://www.la-press.com/neurocognitive-treatment-for-a-patient-with-alzheimers-disease-using-a-article-a6014>
- [51] Fitbit Inc., “Help article: What should I know about my heart rate data?” 2017. [Online]. Available: https://help.fitbit.com/articles/en_US/Help_article/1565
- [52] J. Allen, “Photoplethysmography and its application in clinical physiological measurement,” *Physiol. Meas*, vol. 28, pp. 1–39, 2007. [Online]. Available: <http://iopscience.iop.org/article/10.1088/0967-3334/28/3/R01/pdf>
- [53] R. Wang, G. Blackburn, M. Desai, D. Phelan, L. Gillinov, P. Houghtaling, M. Gillinov, C. MA, M. H, L. RMT, T. DJ, E.-A. F, and P. MS, “Accuracy of Wrist-Worn Heart Rate Monitors,” *JAMA Cardiology*, vol. 313, no. 6, pp. 625–626, oct 2016. [Online]. Available: <http://cardiology.jamanetwork.com/article.aspx?doi=10.1001/jamacardio.2016.3340>
- [54] Fitbit Inc., “Help article: How does my Fitbit device count steps?” 2017. [Online]. Available: https://help.fitbit.com/articles/en_US/Help_article/1143
- [55] —, “Help article: How accurate are Fitbit devices?” 2017. [Online]. Available: https://help.fitbit.com/articles/en_US/Help_article/1136
- [56] K. M. Diaz, D. J. Krupka, M. J. Chang, J. Peacock, Y. Ma, J. Goldsmith, J. E. Schwartz, and K. W. Davidson, “Fitbit?: An accurate and reliable device for wireless physical activity tracking,” 2015.
- [57] A. C. Acta, C. Beleites, U. Neugebauer, T. Bocklitz, C. Krafft, and J. Popp, “Sample size planning for classification models,” *Analytica Chimica Acta*, vol. 760, pp. 25–33, jan 2013. [Online]. Available: https://ac.els-cdn.com/S0003267012016479/1-s2.0-S0003267012016479-main.pdf?_tid=9248c51a-ab1f-11e7-8f70-00000aacb362&acdnat=1507353954_b1a7e3043cc488c46517c991cdb35d61http://www.sciencedirect.com/science/article/pii/S0003267012016479?via%3Dihub
- [58] R. L. Figueroa, Q. Zeng-Treitler, S. Kandula, and L. H. Ngo, “Predicting sample size required for classification performance,” *BMC Medical Informatics and Decision Making*, vol. 12, no. 1, p. 8, dec 2012. [Online]. Available: <http://bmcmmedinformdecismak.biomedcentral.com/articles/10.1186/1472-6947-12-8>
- [59] J. Brownlee, “How Much Training Data is Required for Machine Learning?” jul 2017. [Online]. Available: <https://machinelearningmastery.com/much-training-data-required-machine-learning/>

- [60] E. Seto, K. J. Leonard, C. Masino, J. A. Cafazzo, J. Barnsley, and H. J. Ross, “Attitudes of heart failure patients and health care providers towards mobile phone-based remote monitoring,” *Journal of Medical Internet Research*, vol. 12, no. 4, pp. 3–12, 2010.
- [61] Analytics Vidhya Content Team, “Tutorial on 5 Powerful R Packages used for imputing missing values,” 2016. [Online]. Available: <https://www.analyticsvidhya.com/blog/2016/03/tutorial-powerful-packages-imputing-missing-values/>
- [62] D. J. Stekhoven, “Package ‘missForest’,” Tech. Rep., 2016. [Online]. Available: <https://cran.r-project.org/web/packages/missForest/missForest.pdf>
- [63] H. Tanaka, K. D. Monahan, and D. R. Seals, “Age-Predicted Maximal Heart Rate Revisited,” 2001. [Online]. Available: <http://www.onlinejacc.org/content/accj/37/1/153.full.pdf?download=false>
- [64] Medscape, “Sectral, (acebutolol) dosing, indications, interactions, adverse effects, and more.” [Online]. Available: <https://reference.medscape.com/drug/sectral-acebutolol-342354>
- [65] D. F. McAuley, “Beta Blockers - common dosage guidelines,” 2017. [Online]. Available: <http://www.globalrph.com/beta.htm>
- [66] Heart and Stroke Foundation, “Beta-blockers — Heart and Stroke Foundation,” 2017. [Online]. Available: <https://www.heartandstroke.ca/heart/treatments/medications/beta-blockers>
- [67] J. O’Connell and S. Højsgaard, “Hidden Semi Markov Models for Multiple Observation Sequences: The mhsmm Package for R,” *Journal of Statistical Software*, vol. 39, no. 4, pp. 1–22, 2011. [Online]. Available: <http://www.jstatsoft.org/index.php/jss/article/view/v039i04/v39i04.pdf>
- [68] —, “Package ‘mhsmm’,” *CRAN*, no. 0.4.16, 2017.
- [69] S. Sayad, “Model Evaluation - Classification,” p. 1. [Online]. Available: [http://chem-eng.utoronto.ca/\\$\sim\\$datamining/dmc/model_evaluation_c.htm](http://chem-eng.utoronto.ca/\simdatamining/dmc/model_evaluation_c.htm)
- [70] MedCalc, “ROC curve analysis with MedCalc,” 2017. [Online]. Available: <https://www.medcalc.org/manual/roc-curves.php>
- [71] J. Davis and M. Goadrich, “The Relationship Between Precision-Recall and ROC Curves,” *ICML ’06 Proceedings of the 23rd international conference on Machine learning*, pp. 233–240, 2006. [Online]. Available: <https://dl.acm.org/citation.cfm?id=1143874>
- [72] P. A. Flach, “ICML’04 tutorial on ROC analysis,” p. 3, 2004. [Online]. Available: [http://www.cs.bris.ac.uk/\\$\sim\\$flach/ICML04tutorial/](http://www.cs.bris.ac.uk/\simflach/ICML04tutorial/)

- [73] Gung and Dsimcha, “ROC vs precision-and-recall curves,” 2013. [Online]. Available: <https://stats.stackexchange.com/questions/7207/roc-vs-precision-and-recall-curves/7210#7210>
- [74] M. Sokolova and G. Lapalme, “A systematic analysis of performance measures for classification tasks,” *Information Processing and Management*, vol. 45, pp. 427–437, 2009. [Online]. Available: <http://rali.iro.umontreal.ca/rali/sites/default/files/publis/SokolovaLapalme-JIPM09.pdf>
- [75] G. Forman and M. Scholz, “Apples-to-Apples in Cross-Validation Studies: Pitfalls in Classifier Performance Measurement,” *SIGKDD Explorations*, vol. 12, no. 1, pp. 49–57, 2010. [Online]. Available: http://www.kdd.org/exploration_files/v12-1-p49-forman-sigkdd.pdf
- [76] V. Van Asch, “Macro- and micro-averaged evaluation measures,” 2013. [Online]. Available: [http://www.cnts.ua.ac.be/~sim\\$vincent/pdf/microaverage.pdf](http://www.cnts.ua.ac.be/~sim$vincent/pdf/microaverage.pdf)
- [77] J. E. Fieldsend and R. M. Everson, “Visualisation of multi-class ROC surfaces,” in *Proceedings of the ICML 2005 workshop on ROC Analysis in Machine Learning*, 2005, pp. 49 – 56. [Online]. Available: [http://users.dsic.upv.es/~sim\\$flip/ROCML2005/papers/fieldsend2CRC.pdf](http://users.dsic.upv.es/~sim$flip/ROCML2005/papers/fieldsend2CRC.pdf)
- [78] F. J. Anscombe, “Graphs in Statistical Analysis,” *The American Statistician*, vol. 27, no. 1, pp. 17–21, 1973. [Online]. Available: <http://www.jstor.org/stable/2682899>
- [79] X. Robin, N. Turck, A. Hainard, N. Tiberti, F. Lisacek, J.-C. Sanchez, M. Müller, and S. Siegert, “Package ‘pROC’,” *CRAN*, no. 1.10, 2017. [Online]. Available: <https://cran.r-project.org/web/packages/pROC/pROC.pdf>
- [80] Y. Yan, “Package ‘MLmetrics’,” *CRAN*, no. 1.1.1, 2016. [Online]. Available: <https://cran.r-project.org/web/packages/MLmetrics/MLmetrics.pdf>
- [81] D. J. Hand and R. J. Till, “A Simple Generalisation of the Area Under the ROC Curve for Multiple Class Classification Problems,” *Machine Learning*, vol. 45, no. 2, pp. 171–186, 2001. [Online]. Available: <http://link.springer.com/10.1023/A:1010920819831https://link.springer.com/content/pdf/10.1023%2FA%3A1010920819831.pdf>
- [82] R. Hyndman, Chl, A. W, Garak, and A. Grigorev, “How to plot ROC curves in multiclass classification?” jul 2010. [Online]. Available: <https://stats.stackexchange.com/a/32101>
- [83] T. Kautz, B. M. Eskofier, and C. F. Pasluosta, “Generic performance measure for multiclass-classifiers,” *Pattern Recognition*, vol. 68, pp. 111–125, 2017. [Online]. Available: https://ac.els-cdn.com/S0031320317301073/1-s2.0-S0031320317301073-main.pdf?_tid=be702404-bf55-11e7-a7f8-00000aabb0f6b&acdnat=1509576245_ed9d4621d0296ad7dd85a6839296e0e1

- [84] G. Tsoumakas, I. Katakis, and I. Vlahavas, “Mining Multi-label Data,” in *Data Mining and Knowledge Discovery Handbook*. Boston, MA: Springer US, 2009, pp. 667–685. [Online]. Available: http://link.springer.com/10.1007/978-0-387-09823-4_34
- [85] F. Sebastiani, “Machine Learning in Automated Text Categorization,” *ACM Computing Surveys*, vol. 34, no. 1, pp. 1–47, 2002. [Online]. Available: <http://nmis.isti.cnr.it/sebastiani/Publications/ACMCS02.pdf>
- [86] A. Rehman, K. Javed, and H. Babri, “Feature selection based on a normalized difference measure for text classification,” *Information Processing and Management*, vol. 53, no. 2, pp. 473–489, 2017. [Online]. Available: <http://www.sciencedirect.com/science/article/pii/S0306457316307051>
- [87] J. Du, J. Xu, H. Song, X. Liu, and C. Tao, “Optimization on machine learning based approaches for sentiment analysis on HPV vaccines related tweets,” *Journal of Biomedical Semantics*, vol. 8, no. 9, 2017. [Online]. Available: <https://jbiomedsem.biomedcentral.com/track/pdf/10.1186/s13326-017-0120-6?site=jbiomedsem.biomedcentral.com>
- [88] F. Kayaalp, A. Zengin, R. Kara, and S. Zavrak, “Leakage detection and localization on water transportation pipelines: a multi-label classification approach,” *Neural Computing and Applications*, vol. 28, no. 10, pp. 2905–2914, oct 2017. [Online]. Available: <http://link.springer.com/10.1007/s00521-017-2872-4>
- [89] S. Wang, J. Wang, Z. Wang, and Q. Ji, “Enhancing multi-label classification by modeling dependencies among labels,” *Pattern Recognition*, vol. 47, no. 10, pp. 3405–3413, oct 2014. [Online]. Available: <http://linkinghub.elsevier.com/retrieve/pii/S003132031400154X>
- [90] C. D. Manning, P. Raghavan, and H. Schütze, “Text Classification and Naive Bayes,” in *Introduction to Information Retrieval*. Cambridge: Cambridge University Press, 2009, ch. 13, pp. 253–288. [Online]. Available: <https://nlp.stanford.edu/IR-book/pdf/irbookonlinereading.pdf>
- [91] T. Segaran, *Programming collective intelligence : building smart web 2.0 applications*. O’Reilly, 2007.
- [92] M. J. Sandel, *Justice: What’s the Right Thing to Do?* Harvard Justice. Farrar, Straus and Giroux, 2010. [Online]. Available: <http://justiceharvard.org/justice-whats-the-right-thing-to-do/>